The HYDRASHIFT daratumumab and isatuximab in vitro (IVD) diagnostic test resulting of a collaboration between Sebia, Janssen and Sanofi to provide the clinical community with better tools to monitor patients with multiple myeloma in line with the International Myeloma Group’s (IMWG) latest recommendations.
These assays, intended to be used with HYDRAGEL IF, mitigates the daratumumab or isatuximab mediated interference seen in immunofixation results for patients treated with DARZALEX® or SARCLISA®, a fully human monoclonal antibody that binds to CD38.
The benefit of HYDRASHIFT has been highlighted in several scientific publications, such as the Journal of Applied Laboratory Medicine (JALM) by AACC by Thoren, Ola Landgren et al., which shows:
- HYDRASHIFT benefits for myeloma patients who are receiving daratumumab therapy through more accurate monitoring of their disease status.
- The HYDRASHIFT 2/4 daratumumab assay is a useful tool to clarify the source of an IgGk band on immunofixation and allow a patient’s M protein to be viewed without interference.
HYDRASYS 2 SCAN FOCUSING
Um vasto menu com resultados de alta qualidade em eletroforese em gel.
Saiba mais sobre as nossas tecnologias exclusivas
Esta seção contém informações destinadas a ampla distribuição e, portanto, pode conter detalhes do produto ou informações que não estão disponíveis ou sejam válidas no seu país.
Entre em contato com o seu representante Sebia local. Informações destinadas a profissionais de saúde.
Leia atentamente as instruções nos folhetos informativos dos reagentes e nos manuais dos instrumentos.